Literature DB >> 29155163

Antifungal azoles itraconazole and posaconazole exhibit potent in vitro antiviral activity against clinical isolates of parechovirus A3 (Picornaviridae).

Eric Rhoden1, W Allan Nix1, William C Weldon2, Rangaraj Selvarangan3.   

Abstract

Parechovirus A3 (Par-A3, formerly human parechovirus 3) is an emerging viral infection of the central nervous system in children. We used an automated, homogeneous, cell based assay to identify itraconazole and posaconazole as inhibitors of Par-A3, with antiviral activity below concentrations clinically attainable in pediatric patients. Currently, there is no approved antiviral treatment for Par-A3 infection, despite numerous reports of serious Par-A3 disease in neonates and infants.
Copyright © 2017. Published by Elsevier B.V.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29155163      PMCID： PMC9169550          DOI： 10.1016/j.antiviral.2017.11.011

Source DB:  PubMed          Journal:  Antiviral Res        ISSN： 0166-3542            Impact factor:   10.103


  12 in total

1.  Arginine-glycine-aspartic acid motif is critical for human parechovirus 1 entry.

Authors:  Y Boonyakiat; P J Hughes; F Ghazi; G Stanway
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

2.  Comparison of human parechovirus and enterovirus detection frequencies in cerebrospinal fluid samples collected over a 5-year period in edinburgh: HPeV type 3 identified as the most common picornavirus type.

Authors:  Heli Harvala; Nigel McLeish; Jasmina Kondracka; Chloe L McIntyre; E Carol McWilliam Leitch; Kate Templeton; Peter Simmonds
Journal:  J Med Virol       Date:  2011-05       Impact factor: 2.327

3.  Discovery of itraconazole with broad-spectrum in vitro antienterovirus activity that targets nonstructural protein 3A.

Authors:  Qianqian Gao; Shilin Yuan; Chao Zhang; Ying Wang; Yizhuo Wang; Guimei He; Shuyi Zhang; Ralf Altmeyer; Gang Zou
Journal:  Antimicrob Agents Chemother       Date:  2015-02-17       Impact factor: 5.191

4.  Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children.

Authors:  L de Repentigny; J Ratelle; J M Leclerc; G Cornu; E M Sokal; P Jacqmin; K De Beule
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191

5.  Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis.

Authors:  Andreas H Groll; Lauren Wood; Maureen Roden; Diana Mickiene; Christine C Chiou; Ellen Townley; Luqman Dad; Stephen C Piscitelli; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

6.  Human parechovirus central nervous system infections in southern California children.

Authors:  Susanna Felsenstein; Shangxin Yang; Natalie Eubanks; Edwin Sobrera; John P Grimm; Grace Aldrovandi
Journal:  Pediatr Infect Dis J       Date:  2014-04       Impact factor: 2.129

7.  Human parechovirus 3 and neonatal infections.

Authors:  Guy Boivin; Yacine Abed; François D Boucher
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

8.  Parechovirus Genotype 3 Outbreak among Infants, New South Wales, Australia, 2013-2014.

Authors:  Germaine Cumming; Ameneh Khatami; Brendan J McMullan; Jennie Musto; Kit Leung; Oanh Nguyen; Mark J Ferson; Georgina Papadakis; Vicky Sheppeard
Journal:  Emerg Infect Dis       Date:  2015-07       Impact factor: 6.883

9.  Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation.

Authors:  Michaela Döring; Carsten Müller; Pascal-David Johann; Annika Erbacher; Astrid Kimmig; Carl-Philipp Schwarze; Peter Lang; Rupert Handgretinger; Ingo Müller
Journal:  BMC Infect Dis       Date:  2012-10-19       Impact factor: 3.090

10.  Human parechovirus infection, Denmark.

Authors:  Thea K Fischer; Sofie Midgley; Camilla Dalgaard; Alex Y Nielsen
Journal:  Emerg Infect Dis       Date:  2014-01       Impact factor: 6.883
View more
  8 in total

1.  Antifungal Triazole Posaconazole Targets an Early Stage of the Parechovirus A3 Life Cycle.

Authors:  Eric Rhoden; Terry Fei Fan Ng; Ray Campagnoli; W Allan Nix; Jennifer Konopka-Anstadt; Rangaraj Selvarangan; Laurence Briesach; M Steven Oberste; William C Weldon
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

2.  Antiviral activity and mechanism of the antifungal drug, anidulafungin, suggesting its potential to promote treatment of viral diseases.

Authors:  Shu Shen; Yaxian Zhang; Zhiyun Yin; Qiong Zhu; Jingyuan Zhang; Tiantian Wang; Yaohui Fang; Xiaoli Wu; Yuan Bai; Shiyu Dai; Xijia Liu; Jiayin Jin; Shuang Tang; Jia Liu; Manli Wang; Yu Guo; Fei Deng
Journal:  BMC Med       Date:  2022-10-21       Impact factor: 11.150

3.  The Clinically Approved Antifungal Drug Posaconazole Inhibits Human Cytomegalovirus Replication.

Authors:  Beatrice Mercorelli; Anna Luganini; Marta Celegato; Giorgio Palù; Giorgio Gribaudo; Galina I Lepesheva; Arianna Loregian
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

Review 4.  Potential COVID-19 therapeutics from a rare disease: weaponizing lipid dysregulation to combat viral infectivity.

Authors:  Stephen L Sturley; Tamayanthi Rajakumar; Natalie Hammond; Katsumi Higaki; Zsuzsa Márka; Szabolcs Márka; Andrew B Munkacsi
Journal:  J Lipid Res       Date:  2020-05-26       Impact factor: 5.922

Review 5.  Parechovirus A Pathogenesis and the Enigma of Genotype A-3.

Authors:  Adithya Sridhar; Eveliina Karelehto; Lieke Brouwer; Dasja Pajkrt; Katja C Wolthers
Journal:  Viruses       Date:  2019-11-14       Impact factor: 5.048

6.  Role of Endolysosomes in Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Coronavirus Disease 2019 Pathogenesis: Implications for Potential Treatments.

Authors:  Nabab Khan; Xuesong Chen; Jonathan D Geiger
Journal:  Front Pharmacol       Date:  2020-10-29       Impact factor: 5.810

7.  A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.

Authors:  Bernhard Ellinger; Denisa Bojkova; Andrea Zaliani; Jindrich Cinatl; Carsten Claussen; Sandra Westhaus; Oliver Keminer; Jeanette Reinshagen; Maria Kuzikov; Markus Wolf; Gerd Geisslinger; Philip Gribbon; Sandra Ciesek
Journal:  Sci Data       Date:  2021-02-26       Impact factor: 6.444

Review 8.  Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.

Authors:  Leena Abdulaziz; Esraa Elhadi; Ejlal A Abdallah; Fadlalbaseer A Alnoor; Bashir A Yousef
Journal:  J Exp Pharmacol       Date:  2022-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.